Skip to main content
. Author manuscript; available in PMC: 2021 Jul 1.
Published in final edited form as: Hypertension. 2020 Jun 1;76(1):3–15. doi: 10.1161/HYPERTENSIONAHA.120.13898

Figure 2. Left Panel:

Figure 2

Decreased CYP epoxygenase activity or increased sEH activity results in decreased epoxyeicosatrienoic acids (EETs) resulting in vascular dysfunction, inflammation, impaired pressure natriuresis, organ fibrosis, and hypertension mediated renal and cardiovascular (CV) complications.

Right Panel: Epoxyeicosatrienoic acid (EET) analogs and soluble epoxide hydrolase (sEH) improve vascular function, decrease inflammation, increase natriuresis, combat cardiovascular (CV) diseases, lower blood pressure, combat kidney diseases.